Mitoxantrone Hydrochloride

6 trials 5 recruiting LOncology

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

5 Recruiting

1 Completed trials

6 Sponsors

19 Countries

Phase III

Phase II

Phase I/II

Phase IV

Phase III: 2 Phase II: 1 Phase I/II: 1 Phase IV: 2

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Myelodysplastic syndrome 1

Sponsors using this IMP

GPOH gGmbH 1 Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. 1 Medizinische Hochschule Hannover 1 Pfizer Inc. 1 Robert Bosch Gesellschaft fuer medizinische Forschung mbH 1 Technische Universitat Dresden 1

All trials

6 total

IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting

2024-514517-35-00 Phase III 7 countries Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting

2023-509810-13-00 Phase II 16 countries Pfizer Inc.
Serial cardiac magnetic resonance imaging (CMR) with contrast agents and biomarker analysis for the detection of cardiotoxicity under anthr… Recruiting

2025-521573-14-00 Phase IV 1 country Robert Bosch Gesellschaft fuer medizinische Forschung mbH
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua… Recruiting

2024-512503-39-00 Phase IV 3 countries Medizinische Hochschule Hannover
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting

2022-500783-35-00 Phase III 6 countries GPOH gGmbH
Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended

2024-514018-12-00 Phase I/II 1 country Technische Universitaet Dresden

Showing 1–6 of 6 trials

← All drugs A–Z